Akums Drugs Q1 FY27 Results (NSE: AKUMS)
Signal: Margin expansion
The read
The trajectory improved at the group level: consolidated revenue grew 13.9% YoY and derived EBITDA margin expanded approximately 238bps to 15.0%, driving PAT up 71.7% to ₹1,109.78 million; however, standalone PAT remained flat at ₹448.39 million and the lower consolidated tax rate of approximately 27.5% versus 48.4% also amplified earnings growth.
| Metric | Value | YoY | QoQ |
|---|---|---|---|
| Revenue | ₹1,166.63 Cr | +13.9% | +0.8% |
| Net profit | ₹110.98 Cr | +71.7% | |
| EBIT margin | 14.97% |
P&L walk
Consolidated revenue from operations rose to ₹11,666.29 million, +13.9% YoY and +0.8% QoQ, while gross margin expanded to approximately 44.6% from 43.2% and derived EBITDA margin improved to approximately 15.0% from 12.6%; PAT increased 71.7% to ₹1,109.78 million, helped by the lower effective tax rate of 27.5%.
Segments
The company reports a single Pharmaceuticals segment, but the consolidated-versus-standalone divergence is material: consolidated PAT was ₹1,109.78 million versus standalone PAT of ₹448.39 million, with group PAT up 71.7% YoY while standalone PAT was flat.
Key positives
- Consolidated revenue from operations increased 13.9% YoY to ₹11,666.29 million, improving from 9.7% growth in Q4FY26.
- Derived consolidated EBITDA margin expanded approximately 238bps YoY to 14.97%, with raw-material and stock-in-trade costs declining to approximately 60.8% of revenue from 63.6%.
- Consolidated PAT rose 71.7% YoY to ₹1,109.78 million, supported by 45.5% growth in profit before tax and a lower effective tax rate of approximately 27.5%.
Key concerns
- Standalone PAT was broadly flat at ₹448.39 million despite 15.9% YoY growth in total income, and standalone gross margin contracted approximately 428bps to 37.1%.
- Consolidated PAT growth of 71.7% exceeded revenue growth of 13.9% partly because the effective tax rate fell to approximately 27.5% from 48.4% YoY, reducing the quality of the headline earnings growth.
- Consolidated EPS is not disclosed in the provided filing text, preventing a PAT-to-EPS dilution check.
Research and educational content only. Not investment advice.